RBC Capital Reiterates Sector Perform on Design Therapeutics, Maintains $4 Price Target
Benzinga Newsdesk 2 years ago
NewsPrice TargetReiterationAnalyst Ratings
RBC Capital analyst Leonid Timashev reiterates Design Therapeutics (NASDAQ:DSGN) with a Sector Perform and maintains $4 price target.
RBC Capital analyst Leonid Timashev reiterates Design Therapeutics (NASDAQ:DSGN) with a Sector Perform and maintains $4 price target.